Detalhe da pesquisa
1.
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC).
J Clin Pharmacol
; 64(3): 362-370, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37694295
2.
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046621
3.
DLL3: an emerging target in small cell lung cancer.
J Hematol Oncol
; 12(1): 61, 2019 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31215500